Paid Clinical Trials Colorado
Discover 1,648 paid clinical trials in Colorado. Search by city or condition to find a research study near you that matches your needs across various therapeutic areas.
Phase 1 Study of RBN-2397, an Oral PARP7 Inhibitor, in Patients With Solid Tumors
Sponsor:
Ribon Therapeutics, Inc.
Location:
Code:
NCT04053673
Conditions
Solid Tumor, Adult
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
RBN-2397
ALLIANCE AVIV: Safety and Effectiveness of the SAPIEN X4 Transcatheter Heart Valve in Failing Aortic Bioprosthetic Valves
Sponsor:
Edwards Lifesciences
Location:
Code:
NCT05172973
Conditions
Aortic Valve Insufficiency
Aortic Valve Stenosis
Eligibility Criteria
Sex: All
Age: 0 - 70+
Healthy Volunteers: Not accepted
Interventions
SAPIEN X4 THV
A Study of TAK-186 (Also Known as MVC-101) in Adults With Advanced or Metastatic Cancer
Sponsor:
Takeda
Location:
Code:
NCT04844073
Conditions
Squamous Cell Cancer of Head and Neck (SCCHN)
Non-small Cell Lung Cancer (NSCLC)
Colorectal Cancer
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
TAK-186
Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread
Sponsor:
Gilead Sciences
Location:
Code:
NCT03547973
Conditions
Metastatic Urothelial Cancer
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Sacituzumab Govitecan-hziy
Pembrolizumab
Cisplatin
Avelumab
Zimberelimab
Impact of Respiratory Training in Lymphoma Survivors
Sponsor:
University of Colorado, Denver
Location:
Code:
NCT05938127
Conditions
Hodgkin Lymphoma
Non Hodgkin Lymphoma
Eligibility Criteria
Sex: All
Age: 18 - 70+
Healthy Volunteers: Not accepted
Interventions
Inspiratory muscle strength training
Sham Inspiratory muscle strength training
Study to Evaluate the Efficacy and Safety of K-877-ER and CSG452 in Participants With NASH With Liver Fibrosis
Sponsor:
Kowa Research Institute, Inc.
Location:
Code:
NCT05327127
Conditions
NASH
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
K-877-ER
CSG452
Placebo
A Study to Evaluate Efficacy and Safety of MELT-300 for Procedural Sedation in Subjects Undergoing Cataract Extraction With Lens Replacement (CELR)
Sponsor:
Melt Pharmaceuticals
Location:
Code:
NCT06383273
Conditions
Cataract
Eligibility Criteria
Sex: All
Age: 18 - 65
Healthy Volunteers: Not accepted
Interventions
MELT-300 sublingual tablet
Midalozam sublingual tablet
Placebo sublingual tablet
Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)
Sponsor:
Merck Sharp & Dohme LLC
Location:
Code:
NCT02861573
Conditions
Metastatic Castration-Resistant Prostate Cancer
Eligibility Criteria
Sex: Male
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Pembrolizumab 200 mg
Olaparib 400 mg
Docetaxel 75 mg/m^2
Prednisone 5 mg
Enzalutamide 160 mg
Epidemiological Study to Monitor Study Participants With Resected Stage II (High Risk) or Stage III Colorectal Cancer for Circulating Tumor DNA Before, During and After Their Treatment With Adjuvant Chemotherapy
Sponsor:
BioNTech SE
Location:
Code:
NCT04813627
Conditions
Colorectal Cancer Stage II
Colorectal Cancer Stage III
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Regular blood sample collection for ctDNA assessment